# Pharvaris (PHVS) — News

PHVS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/phvs/news

## Recent headlines

- [Pharvaris N.V.: RBC raises target price to $62 from $52](https://www.ainvest.com/news/pharvaris-rbc-raises-target-price-62-52-2609) — AInvest Wire, Sep 9, 2026
  RBC Capital Markets has raised its target price for Pharvaris N.V. (PHVS) to $62 from $52, reflecting a positive reassessment of the company’s outlook. The adjustment follows recent stock price momentum, with PHVS trading near the top of its 52-week range and above its 200-day simple moving average…
- [Pharvaris: KBC Securities raises target price to $49 from $39; rating buy](https://www.ainvest.com/news/pharvaris-kbc-securities-raises-target-price-49-39-rating-buy-2609) — AInvest Wire, Sep 9, 2026
- [Shares of Pharvaris up 14% after co's genetic disorder drug meets main goal in late-stage trial](https://www.ainvest.com/news/shares-pharvaris-14-genetic-disorder-drug-meets-main-goal-late-stage-trial-2609) — AInvest Wire, Sep 8, 2026
- [Shares of Pharvaris up 26.5% premarket after co's genetic disorder drug meets main goal in late-stage trial](https://www.ainvest.com/news/shares-pharvaris-26-5-premarket-genetic-disorder-drug-meets-main-goal-late-stage-trial-2609) — AInvest Wire, Sep 8, 2026
  Pharvaris N.V. (Nasdaq: PHVS) shares rose 26.5% in premarket trading on September 8, 2026, following the announcement that its experimental drug PHVS416 met all primary and secondary endpoints in a Phase 2 trial for the treatment of hereditary angioedema (HAE). The drug, which targets bradykinin…
- [Pharvaris' Chapter-3 meets all primary, secondary endpoints](https://www.ainvest.com/news/pharvaris-chapter-3-meets-primary-secondary-endpoints-2609) — AInvest Wire, Sep 8, 2026
  Pharvaris Pharmaceuticals announced that its Phase 3 clinical trial for its lead candidate, PHV-301, has successfully met all primary and secondary endpoints [1]. The trial, which enrolled over 1,200 patients across 40 global sites, evaluated the drug’s efficacy and safety in treating moderate to…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).